EAACI Congress 2024
BackBiologicals 3
Sunday 02 Jun, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
A Phase 3 Open-Label Trial-In-Progress Evaluating Garadacimab For Prophylactic Treatment Of Pediatric Patients (Aged 2–11 Years) With Hereditary Angioedema
12:00
Characterization of anti-IgE molecules to inhibit IgE:receptor interactions and suppress IgE production in B-cells
12:00
Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of tezepelumab in adult patients with severe chronic rhinosinusitis with nasal polyposis (WAYPOINT)
12:00
Effect of anti IL-5/IL-5Rα biological treatment on tissue eosinophil subpopulations in patients affected by Chronic Rhinosinusitis with Nasal Polyp
12:00
Eosinophilic systemic diseases: clinical characterization and efficacy of anti il5/il5-r therapy in a single center italian cohort
12:00
High-affinity omalizumab variants with optimized disruptive efficacy accelerate allergic effector cell desensitization
12:00
MY006: anti-allergen multispecific antibody for the treatment of peanut allergy
12:00
Mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA): a real-life experience in a single-center cohort
12:00
Mepolizumab simultaneously improves clinical outcomes in severe CRSwNP and asthma in the SYNAPSE study: Focus on global airway disease
12:00
Patients with severe eosinophilic asthma starting anti-IL5 treatment after 2018 have better preserved lung function compared to the patients who started treatment earlier
12:00
Real-life experience and the safety of Immunobiologicals in the treatment of immunoallergic diseases
12:00
Response to benralizumab in severe vernal keratoconjunctivitis after treatment failure with omalizumab
12:00
Treating idiopathic hypereosinophilic syndrome in the biologics era: an experience in a developing country
